Taiga Biotechnologies, Inc. is developing a new class of cell-based therapies utilizing autologous immune cells and allogeneic stem cells 

Our Technology

• Specific target NOT required

• No genetic modification

• No expansion of cells

• 4-hour manufacturing process

• Scalable, Reliable, Low Risk

Upcoming Milestones

• TBX-3400 clinical trials

  • Phase 1/2 data for melanoma​

  • Efficacy data for colorectal cancer

  • Efficacy data for hepatitis B and HPV

• Initiation of three additional clinical trials​